|
US3557142A
(en)
|
1968-02-20 |
1971-01-19 |
Sterling Drug Inc |
4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters
|
|
BE790679A
(fr)
|
1971-11-03 |
1973-04-27 |
Ici Ltd |
Derives de l'indole
|
|
DK151884C
(da)
|
1979-03-07 |
1988-06-13 |
Pfizer |
Analogifremgangsmaade til fremstilling af 3-(1-imidazolylalkyl)indolderivater eller farmaceutisk acceptable syreadditionssalte deraf
|
|
US4363912A
(en)
|
1980-12-15 |
1982-12-14 |
Pfizer Inc. |
Indole thromboxane synthetase inhibitors
|
|
US4478842A
(en)
|
1981-11-19 |
1984-10-23 |
Ciba-Geigy Corporation |
N-Substituted-2-pyridylindoles
|
|
GB8607294D0
(en)
|
1985-04-17 |
1986-04-30 |
Ici America Inc |
Heterocyclic amide derivatives
|
|
DE3514696A1
(de)
|
1985-04-24 |
1986-11-06 |
Bayer Ag, 5090 Leverkusen |
N-indolylethyl-sulfonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung
|
|
US5214059A
(en)
|
1989-07-03 |
1993-05-25 |
Hoechst-Roussel Pharmaceuticals Incorporated |
2-(aminoaryl) indoles and indolines as topical antiinflammatory agents for the treatment of skin disorders
|
|
GB9122590D0
(en)
|
1991-10-24 |
1991-12-04 |
Lilly Industries Ltd |
Pharmaceutical compounds
|
|
KR950701317A
(ko)
|
1992-05-08 |
1995-03-23 |
오오쓰까 아끼히꼬 |
인돌 유도체(Indole Derivative)
|
|
IL109309A
(en)
|
1993-04-16 |
2000-06-29 |
Lilly Co Eli |
1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
|
|
GB9317764D0
(en)
|
1993-08-26 |
1993-10-13 |
Pfizer Ltd |
Therapeutic compound
|
|
US5641800A
(en)
|
1994-07-21 |
1997-06-24 |
Eli Lilly And Company |
1H-indole-1-functional sPLA2 inhibitors
|
|
US5532237A
(en)
|
1995-02-15 |
1996-07-02 |
Merck Frosst Canada, Inc. |
Indole derivatives with affinity for the cannabinoid receptor
|
|
US6040426A
(en)
|
1996-06-05 |
2000-03-21 |
Bml, Inc. |
Human Th2 specific protein
|
|
US6828344B1
(en)
|
1998-02-25 |
2004-12-07 |
Genetics Institute, Llc |
Inhibitors of phospholipase enzymes
|
|
US6916841B2
(en)
|
1998-02-25 |
2005-07-12 |
Genetics Institute, Llc |
Inhibitors of phospholipase enzymes
|
|
US6500853B1
(en)
|
1998-02-28 |
2002-12-31 |
Genetics Institute, Llc |
Inhibitors of phospholipase enzymes
|
|
SK7522001A3
(en)
|
1998-03-31 |
2002-02-05 |
Inst For Pharm Discovery Inc |
Substituted indolealkanoic acids
|
|
ATE330955T1
(de)
|
1998-04-28 |
2006-07-15 |
Elbion Ag |
Indolderivate und deren verwendung als inhibitoren der phosphodiesterase 4.
|
|
EP0984012A3
(en)
|
1998-08-31 |
2001-01-10 |
Pfizer Products Inc. |
Nitric oxide releasing oxindole prodrugs with analgesic and anti-inflammatory properties
|
|
TNSN99224A1
(fr)
|
1998-12-01 |
2005-11-10 |
Inst For Pharm Discovery Inc |
Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
|
|
EP1211513B1
(en)
|
1999-08-23 |
2006-01-04 |
BML, Inc. |
Method of identifying modulators of prostaglandin d2 receptors
|
|
WO2001051489A2
(en)
|
2000-01-14 |
2001-07-19 |
The Institutes For Pharmaceutical Discovery, Llc |
Methods for lowering uric acid levels
|
|
WO2001064205A2
(en)
|
2000-03-02 |
2001-09-07 |
The Institutes For Pharmaceutical Discovery, Llc |
Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor
|
|
JP2001247570A
(ja)
|
2000-03-08 |
2001-09-11 |
Japan Tobacco Inc |
インドール酢酸化合物及びその製造方法
|
|
US6878522B2
(en)
|
2000-07-07 |
2005-04-12 |
Baiyong Li |
Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
|
|
US6797708B2
(en)
|
2001-12-03 |
2004-09-28 |
Wyeth |
Inhibitors of cytosolic phospholipase A2
|
|
SE0200411D0
(sv)
|
2002-02-05 |
2002-02-05 |
Astrazeneca Ab |
Novel use
|
|
US7534897B2
(en)
|
2002-05-16 |
2009-05-19 |
Shionogi & Co., Ltd. |
Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism
|
|
TW200307542A
(en)
|
2002-05-30 |
2003-12-16 |
Astrazeneca Ab |
Novel compounds
|
|
SE0201635D0
(sv)
|
2002-05-30 |
2002-05-30 |
Astrazeneca Ab |
Novel compounds
|
|
SE0202241D0
(sv)
|
2002-07-17 |
2002-07-17 |
Astrazeneca Ab |
Novel Compounds
|
|
US7348351B2
(en)
|
2002-12-10 |
2008-03-25 |
Wyeth |
Substituted 3-alkyl and 3-arylalkyl 1H-indol-1yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
|
|
CA2511214C
(en)
|
2002-12-20 |
2012-12-18 |
Tularik, Inc. |
Asthma and allergic inflammation modulators
|
|
SE0301569D0
(sv)
|
2003-05-27 |
2003-05-27 |
Astrazeneca Ab |
Novel compounds
|
|
SE0302232D0
(sv)
|
2003-08-18 |
2003-08-18 |
Astrazeneca Ab |
Novel Compounds
|
|
US20070232681A1
(en)
|
2003-10-14 |
2007-10-04 |
Oxagen Limited |
Compounds Having Crth2 Antagonist Activity
|
|
GB0324763D0
(en)
|
2003-10-23 |
2003-11-26 |
Oxagen Ltd |
Use of compounds in therapy
|
|
KR100761615B1
(ko)
|
2003-11-05 |
2007-10-04 |
에프. 호프만-라 로슈 아게 |
Ｐｐａｒ 활성화제로서 헤테로아릴 유도체
|
|
SE0303180D0
(sv)
|
2003-11-26 |
2003-11-26 |
Astrazeneca Ab |
Novel compounds
|
|
JP2007533725A
(ja)
|
2004-04-20 |
2007-11-22 |
ファイザー・インク |
Ｃｒｔｈ２受容体アンタゴニストを用いたニューロパシー性疼痛処置方法
|
|
WO2005102388A1
(ja)
|
2004-04-26 |
2005-11-03 |
Ono Pharmaceutical Co., Ltd. |
新規なｂｌｔ２介在性疾患、ｂｌｔ２結合剤および化合物
|
|
GB0412914D0
(en)
|
2004-06-10 |
2004-07-14 |
Oxagen Ltd |
Compounds
|
|
EP1805171A4
(en)
|
2004-09-21 |
2009-05-13 |
Wyeth Corp |
CRTH2 RECEPTOR ANTAGONISM DISPLAYING INDIGENOUS ACIDS AND APPLICATIONS THEREOF
|
|
GB2422831A
(en)
|
2005-02-04 |
2006-08-09 |
Oxagen Ltd |
Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor
|
|
GB2422830A
(en)
|
2005-02-04 |
2006-08-09 |
Oxagen Ltd |
Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor
|
|
GB2422829A
(en)
|
2005-02-04 |
2006-08-09 |
Oxagen Ltd |
Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor
|
|
GB0504150D0
(en)
|
2005-03-01 |
2005-04-06 |
Oxagen Ltd |
Microcrystalline material
|
|
GB0505048D0
(en)
|
2005-03-11 |
2005-04-20 |
Oxagen Ltd |
Compounds with PGD antagonist activity
|
|
ES2372701T3
(es)
|
2005-07-22 |
2012-01-25 |
Shionogi & Co., Ltd. |
Derivado de indol que tiene actividad antagonista del receptor de pgd2.
|
|
EP1915372B1
(en)
|
2005-08-12 |
2013-11-20 |
Merck Canada Inc. |
Indole derivatives as crth2 receptor antagonists
|
|
GB0518783D0
(en)
|
2005-09-14 |
2005-10-26 |
Argenta Discovery Ltd |
Indolizine compounds
|
|
GB0605743D0
(en)
|
2006-03-22 |
2006-05-03 |
Oxagen Ltd |
Salts with CRTH2 antagonist activity
|
|
GB0614066D0
(en)
|
2006-07-14 |
2006-08-23 |
Glaxo Group Ltd |
Compounds
|
|
GB0614068D0
(en)
|
2006-07-14 |
2006-08-23 |
Glaxo Group Ltd |
Compounds
|
|
AU2007279079A1
(en)
|
2006-07-22 |
2008-01-31 |
Oxagen Limited |
Compounds having CRTH2 antagonist activity
|
|
WO2009037503A2
(en)
|
2007-09-18 |
2009-03-26 |
Astrazeneca Ab |
New combination - 012 for the treatment of respiratory diseases
|
|
GB0722203D0
(en)
|
2007-11-13 |
2007-12-19 |
Oxagen Ltd |
Use of CRTH2 antagonist compounds
|
|
GB0722216D0
(en)
|
2007-11-13 |
2007-12-27 |
Oxagen Ltd |
Use of crth2 antagonist compounds
|
|
PT2229358E
(pt)
|
2007-12-14 |
2011-06-29 |
Pulmagen Therapeutics Asthma Ltd |
Indoles e sua utilização terapêutica
|
|
EP2245010A1
(en)
|
2008-01-18 |
2010-11-03 |
Pulmagen Therapeutics (Asthma) Limited |
Indoles active on crth2 receptor
|
|
US7750027B2
(en)
|
2008-01-18 |
2010-07-06 |
Oxagen Limited |
Compounds having CRTH2 antagonist activity
|
|
SI2250161T1
(sl)
*
|
2008-01-18 |
2014-04-30 |
Atopix Therapeutics Limited |
Spojine, ki imajo aktivnost crth2 antagonista
|
|
JP2011509991A
(ja)
|
2008-01-22 |
2011-03-31 |
オキサジェン リミテッド |
Ｃｒｔｈ２アンタゴニスト活性を有する化合物
|
|
JP2011509990A
(ja)
|
2008-01-22 |
2011-03-31 |
オキサジェン リミテッド |
Ｃｒｔｈ２アンタゴニスト活性を有する化合物
|
|
US8501959B2
(en)
|
2008-06-24 |
2013-08-06 |
Panmira Pharmaceuticals, Llc |
Cycloalkane[B]indole antagonists of prostaglandin D2 receptors
|
|
GB201103837D0
(en)
|
2011-03-07 |
2011-04-20 |
Oxagen Ltd |
Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
|
|
GB201121557D0
(en)
|
2011-12-15 |
2012-01-25 |
Oxagen Ltd |
Process
|
|
EP2790696A1
(en)
|
2011-12-16 |
2014-10-22 |
Atopix Therapeutics Limited |
Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
|
|
GB201322273D0
(en)
|
2013-12-17 |
2014-01-29 |
Atopix Therapeutics Ltd |
Process
|
|
GB201407820D0
(en)
|
2014-05-02 |
2014-06-18 |
Atopix Therapeutics Ltd |
Polymorphic form
|
|
GB201407813D0
(en)
|
2014-05-02 |
2014-06-18 |
Atopix Therapeutics Ltd |
Polymorphic form
|